Sidock@home is an international volunteer computing project aimed at drug discovery. The first mission of the project is discovery of possible drugs against the SARS-CoV-2 virus. It started as an extension of the project COVID.SI to engage the BOINC community into the drug discovery.
COVID.SI is a citizen science project to fight against SARS-CoV-2 by distributed computing.
You can help with your computer. With the help of BOINC, you will download a subset of compounds on your computer, examine the compounds in the context of the studied target and send the results to a server where they are collected for later analysis.
For account creation please use a Crunch_4Science invitation code. It is not needed when registering by BOINC Manager.
Already joined? Log in.
From chat in BoincWorksop Day 2
"I'm seeing far fewer people interested in running BOINC and many are giving up due to too few "legitimate" projects continuing their research - too many projects have used volunteers and then stopped."
"So, we need more "interesting" projects so people can crunch them...far more people got involved with SiDock, Rosetta and WCG when they launched Covid-19 research tasks..".
Our community is on the right way ;-)
21 Apr 2021, 19:10:17 UTC · Discuss
Upcoming conference: ANTYCOVID-21 (online)
on June 28-29 2021, there will be a scientific conference "ANTYCOVID-21: Computer science protecting human society against epidemics", in an online format, hosted in Poland. We aim to present a talk about SiDock@home and will be glad to see all of you as listeners. We also encourage you to submit own works if you participate in a covid-related research!
15 April 30 May (extended)
Notification of paper acceptance: 15 May
Final paper submission and registration: 30 May
Conference 28-29 June 2020
The papers should be submitted via Easychair
The submission may include long papers limited to 12 pages in Springer LaTex llncs format or short papers (up to 4 pages)
All questions about submissions may be emailed to antycovid21 at easychair.org
2 Apr 2021, 11:27:23 UTC · Discuss
Fifth Target is SARS-CoV-2 EProtein
Our fifth target is the E protein. We are emotionally attached to this protein because we explored its druggability in the early days of our project in the context of Covid.
At only 75 amino acids long, the envelope protein (E) is the smallest of the four structural proteins that make up the SARS-CoV-2 virus particle, and it is essential for the virus to infect cells. Data from other coronaviruses led researchers to suspect that groups of five E proteins form a pore that spans the lipid bilayer membrane of the virus. However, there was no direct evidence because the structural characterization of membrane-spanning proteins is difficult with the most commonly used techniques - X-ray crystallography and cryo-electron microscopy. Mei Hong's group at the Massachusetts Institute of Technology instead used nuclear magnetic resonance spectroscopy to solve the structure of the E protein and confirm pore formation (Nat. Struct. Mol. Biol. 2020, DOI: 10.1038/s41594-020-00536-8). The group also investigated how two drugs, amantadine, and hexamethylene amiloride, can bind to and block the pore. Although these drugs only bind weakly to the pore, the researchers say the new structural information could help in the development of drugs that target the virus.
In our HTVS, we will screen 1 billion of the small molecules to the pore of the E protein pentamer. We hope to find some nice molecules that can block the pore ;-)
19 Mar 2021, 21:50:22 UTC · Discuss
SiDock@home becomes a general drug discovery project
We are happy to announce that SiDock@home will continue as a general drug discovery project, not limited to coronavirus only! This means that the project will continue for a long time. We aim to develop and incorporate novel methods of drug design and perform drug discovery for different diseases.
Nevertheless, the first mission on fighting the coronavirus continues! There are many results to process and more targets to explore within what started from COVID.SI project.
With best wishes,
Natalia and the team.
27 Feb 2021, 14:06:38 UTC · Discuss
Fourth target (corona_RdRp_v1)
We are glad to announce the fourth target, corona_RdRp_v1. This molecule is frequently used in research studies as a potential target to inhibit viral replication. Specifically, it is SARS-CoV-2 RNA-dependent RNA polymerase (RdRp in short), an enzyme which coronavirus SARS-CoV-2 uses for the replication of its genome and the transcription of its genes.
8 Feb 2021, 8:17:30 UTC · Discuss
©2021 SiDock@home Team